360 Stem Cell & Regenerative Medicine Newsletter- June 11, 2015

 weSRCH's Best of the Internet Award

360 Stem Cell & Regenerative Medicine Newsletter - June 11, 2015

Featured Video from from Patient Power: Is CAR T-Cell Therapy the Future of Cancer Treatment?

“Dr. David Maloney, an associate professor of medicine at the University of Washington, discusses his excitement over CAR T-cell (Chimeric Antigen Receptor) therapy expansion. As a leader in this research, Dr. Maloney describes the wave of research efforts behind this adoptive T-cell therapy using the patients’ own immune cells to fight back against the cancer, including blood cancers like chronic lymphocytic leukemia (CLL). Dr. Maloney provides insight on the process of collecting T cells and what the future holds for CARs therapy and its potential extension to not only blood cancers, but perhaps broadening its application in lymphoma, lung, ovarian and other solid tumors.”
World Stem Cell Summit
Celgene to Pay bluebird bio $25 Million in New Research Funding- bluebird bio to Independently Invest in and Pursue a Broad T cell-Based Immuno-oncology Strategy
“Celgene and bluebird bio will work collaboratively on the initial, lead anti-BCMA product candidate (bb2121), with a Phase 1 clinical trial expected to begin enrollment in early 2016, and develop next-generation anti-BCMA product candidates. bluebird bio retains sole rights to develop all other chimeric antigen receptor (CAR) T cell programs developed by bluebird bio under the collaboration, including ongoing undisclosed preclinical programs with opportunities in both solid tumors and hematologic malignancies.”
Positive Trial Results Of Mesoblast Cell Therapy In Patients With Diabetes And Advanced Chronic Kidney Disease
“Mesoblast Limited results from the Company's Phase 2 trial in patients with diabetic nephropathy showed that a single infusion of its intravenously delivered allogeneic mesenchymal precursor cell (MPC) product candidate MPC-300-IV was safe, reduced damaging inflammation, and preserved or improved renal function over at least 24 weeks.”
Financial Review (Australia): Mesoblast Eyes Pharma Deals After Diabetes Trial Success
Success breeds success. This Financial Review article suggests how Mesoblast might leverage the latest cell therapy “blockbuster.”
The Baltimore Sun: Maryland Stem Cell Research Panel Approves 29 Projects for $9.4M in Grants
The awards address diseases and conditions such as diabetes, Gaucher, Alzheimer’s, Parkinson’s, mental disorders, autism, and obesity.
Asterias Biotherapeutics: First Patient Treated in Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury
Asterias is heir to the famous Geron first-ever FDA approved clinical trial using human embryonic stem cells. The cells used in the subject trial are an “oligodendrocyte progenitor population derived from human embryonic stem cells.” The company says that these cell populations have “three potentially reparative functions that address the complex pathologies observed at the injury site of a spinal cord injury.”
UTV Ireland: Galway stem cell treatment receives €6m in funding
“A Galway based cell therapy treatment for combating kidney disease has received €6m in funding from the European Union.”
The Japan Times: Engineers Develop Device to Create Superthin Threads from Live Human Cells
“A team of researchers led by Makoto Nakamura of Toyama University has developed a device to make superthin threads from live human cells that they hope to turn into organs and blood vessels. The researchers mixed live human cells with gel and inserted them into the nozzle of a super-thin hole. The resulting thread can be bundled or woven into three-dimensional objects much like fabric is woven from thread.”
Wake Forest
Harvard Gazette: Injectable Device Delivers Nano-view of the Brain
“It’s a notion that might have come from the pages of a science-fiction novel — an electronic device that can be injected directly into the brain, or other body parts, and treat everything from neurodegenerative disorders to paralysis.
An international team of researchers has developed a method of fabricating nanoscale electronic scaffolds that can be injected via syringe. The scaffolds can then be connected to devices and used to monitor neural activity, stimulate tissues, or even promote regeneration of neurons.” The research is described in a paper in Nature Nanotechnology.
Akron Biotech and Cognate BioServices Announce Strategic Partnership
Cognate BioServices, Inc. and Akron Biotechnology, LLC have entered into a strategic partnership that brings two industry leaders together to provide a more complete package of services to their clients. Cognate is a leader in the provision of cGMP manufacturing services and regulatory support to companies and institutions engaged in the development of regenerative medicine and cell-based products and therapies. Florida-based Akron Biotech, led by intrepid life sciences entrepreneur, Dr. Claudia Zylberberg, is an innovative supplier of validated reagents, solutions and technologies to the cell therapy industry.
Extreme Tech: Mysteries of worm regeneration solved with artificial intelligence
Discovery News: Computer A.I. Solves 120-Year-Old Biological Mystery
360 editor’s comment: Let me get this straight. These articles suggest that artificial intelligence solved the mystery of worm regeneration. What are implications to humankind? Singularity? It’s the stuff of science fiction!
World Stem Cell Summit update: Registration is now open for the 11th World Stem Cell Summit and 2nd RegMed Capital Conference in Atlanta, December 10-12. 225+ speakers and 7 tracks. Recently confirmed speakers include:

Dr. Jan Nolta who directs the UC Davis Stem Cell and Regenerative Cures Program. She is a gifted researcher seeking a cure for Huntington’s Disease.

Canada’s Dr. Michael May who leads the Centre for Commercialization of Regenerative Medicine. The CCRM maintains innovative programs that accelerate commercialization of regenerative technologies.

Dr. Paul Root Wolpe, professor of ethics at Emory University, who recently put together the global meeting “BEINGS 2015.” The conference had astonishing reach. Thought-leaders representing all points of view discussed the trajectory and limits of biotechnology and its impact on the future of the human species.

To learn more about the World Stem Cell Summit and co-located RegMed Capital Conference or to register (pre-early bird discounts apply), click here.

360 Newsletter Editor

Bernard Siegel
Executive Director
Genetics Policy Institute

Stem Cells and the Transformative Power of Hope-a TEDx talk by Bernard Siegel, Editor of 360 Newsletter
Domain: Medical
Category: Biology
weSRCH App on Apple

Recent Newsletters

12 March, 2019
10 October, 2018
15 February, 2018